Logo

ENVB

Enveric Biosciences, Inc.

ENVB

Enveric Biosciences, Inc. • NASDAQ
$5.74 ▼ -2.21% (-0.13)
Market Cap $3.43 M
52w High $1444.50
52w Low $4.88
Dividend Yield 0%
P/E 0
Volume 2.94K
Outstanding Shares 596.98K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.834M ▼ $-1.874M ▲ 0% $-10.81 ▲ $-1.833M ▲
Q2-2025 $0 $2.479M ▲ $-2.519M ▼ 0% $-11.64 ▲ $-2.479M ▼
Q1-2025 $0 $2.107M ▼ $-2.185M ▲ 0% $-14.584K ▼ $-2.104M ▲
Q4-2024 $0 $3.091M ▲ $-3.155M ▼ 0% $-69.84 ▼ $-3.065M ▼
Q3-2024 $0 $1.998M $-2.084M 0% $-43.08 $-1.999M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.758M ▲ $4.362M ▲ $905.885K ▼ $3.456M ▲
Q2-2025 $2.85M ▼ $3.548M ▼ $1.364M ▲ $2.185M ▼
Q1-2025 $4.294M ▲ $5.102M ▲ $1.184M ▼ $3.918M ▲
Q4-2024 $2.241M ▼ $3.083M ▼ $1.49M ▲ $1.593M ▼
Q3-2024 $3.112M $4.79M $839.166K $3.951M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.874M ▲ $-2.075M ▼ $0 $2.992M ▲ $907.778K ▲ $-2.075M ▼
Q2-2025 $-2.519M ▼ $-1.89M ▲ $0 $449.096K ▼ $-1.445M ▼ $-1.89M ▲
Q1-2025 $-2.185M ▲ $-2.392M ▼ $0 $4.449M ▲ $2.053M ▲ $-2.392M ▼
Q4-2024 $-3.155M ▼ $-1.312M ▼ $0 $463.448K ▼ $-870.657K ▼ $-1.312M ▼
Q3-2024 $-2.084M $-927.07K $0 $517.687K $-390.868K $-927.07K

Five-Year Company Overview

Income Statement

Income Statement Enveric is still a pure R&D story with essentially no product or service revenue over the past several years. The company’s costs are driven mainly by research, development, and corporate overhead, which consistently exceed its income. That means it has been running steady operating and net losses, even though the absolute spending level looks relatively modest for the sector. Earnings per share appear extremely volatile and deeply negative, largely because of repeated reverse stock splits and capital structure changes rather than swings in the underlying business. Overall, the income statement reflects an early‑stage biotech that has not yet converted its science into commercial sales and continues to burn cash to advance its pipeline.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of total assets and cash. There is no reported financial debt, which simplifies the capital structure but also underscores that the company mostly depends on equity funding rather than borrowing. Shareholders’ equity is positive but slim, leaving limited cushion to absorb ongoing losses. Taken together, the balance sheet shows a lean, high‑risk early‑stage company: little leverage, but also limited resources to fund long development timelines without new capital. Multiple reverse stock splits over the years signal ongoing efforts to keep the share price within listing requirements and to manage a very fragmented share count, which is a common sign of repeated equity issuance and dilution in small biotech names.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the fact that cash goes out to pay for R&D, staff, and overhead, while no operating cash comes in from product sales. Free cash flow is also negative, though capital spending needs appear modest, so the main cash drain is day‑to‑day operations and research rather than big equipment or facility builds. With no meaningful internal cash generation, the company’s ability to continue funding its pipeline relies on raising money from the outside, whether through issuing new shares, partnerships, grants, or other sources. This dependence on external funding is a central financial risk, especially if capital markets or partner appetite turn less favorable.

Competitive Edge

Competitive Edge Enveric operates in a fast‑moving niche of mental health therapeutics, focusing on psychedelic‑inspired compounds that aim to be non‑hallucinogenic. This is a differentiated scientific angle compared with many psychedelic peers that rely on supervised, hallucinogenic experiences. If successful, Enveric’s approach could open a broader outpatient market and reduce the logistical burden of treatment. Its key potential advantages are a growing library of proprietary molecules, an AI‑supported discovery engine, and a sizeable patent estate around neuroplastogenic compounds. These together can make it harder for direct competitors to copy its exact chemistry and approach. However, the company is still pre‑commercial and early in the clinical journey, while competing against both emerging psychedelic players and large, well‑funded pharmaceutical firms working on depression and anxiety. Until its lead assets show convincing clinical and regulatory progress, its competitive position is more about scientific promise than proven market strength.

Innovation and R&D

Innovation and R&D Innovation is the core of Enveric’s story. The company has built a large internal “Psybrary” of psychedelic‑inspired compounds and uses a proprietary AI platform to design and screen new drug candidates. This allows it to iterate quickly, tune molecules for desired effects, and potentially filter out candidates with safety or tolerability issues early. The lead program, EB‑003, targets specific brain receptors associated with mood and neuroplasticity, but is engineered to avoid hallucinations. If human trials validate this concept, it could represent a new class of treatments that combine the therapeutic promise of psychedelics with the practicality of standard oral medications. Beyond EB‑003, the company is exploring additional compound series that could address several mental health and addiction‑related conditions. It also aims to out‑license some of its library to other players, which, if successful, could provide non‑dilutive funding and external validation. All of this underscores a research‑heavy, high‑risk, high‑uncertainty profile typical of early‑stage biotech: significant upside if the science translates clinically, but meaningful execution and development risk.

Summary

Enveric Biosciences is an early‑stage biotechnology company focused on novel, non‑hallucinogenic, psychedelic‑inspired treatments for mental health disorders. Financially, it has no commercial revenue, a history of ongoing losses, a very small asset and cash base, and repeated reverse stock splits, all of which point to dependence on future financing and share dilution to keep advancing its programs. Strategically, the company is built around its proprietary molecular library, AI‑driven discovery tools, and a growing patent portfolio. These provide a clear scientific and intellectual property angle that could matter if its lead candidates progress successfully through human trials. The aspiration is to deliver convenient, outpatient, orally dosed therapies that avoid the limitations of traditional psychedelic treatments. The key uncertainties lie in clinical proof‑of‑concept, regulatory acceptance, and the ability to secure ongoing funding in a competitive and capital‑intensive field. In essence, ENVB represents a classic high‑risk, research‑centric biotech: minimal current business fundamentals, but a focused innovation platform that could materially change its outlook if its science converts into safe, effective, and approvable medicines.

NEWS

November 26, 2025 · 8:00 AM UTC

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Read more

November 14, 2025 · 4:05 PM UTC

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Read more

October 23, 2025 · 8:00 AM UTC

Enveric Biosciences Announces Reverse Stock Split

Read more

October 16, 2025 · 8:30 AM UTC

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Read more

October 15, 2025 · 8:00 AM UTC

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Read more